bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE - Free Report) in a report issued on Wednesday morning. The brokerage issued a sell rating on the biotechnology company's stock.

A number of other research analysts also recently issued reports on the company. Royal Bank of Canada restated a "sector perform" rating and set a $4.00 price target on shares of bluebird bio in a report on Friday, November 15th. Robert W. Baird cut their price target on bluebird bio from $7.00 to $6.00 and set an "outperform" rating on the stock in a research note on Thursday, August 15th. Bank of America downgraded bluebird bio from a "buy" rating to a "neutral" rating and cut their price target for the stock from $3.00 to $0.50 in a research note on Friday, November 15th. JPMorgan Chase & Co. cut bluebird bio from a "neutral" rating to an "underweight" rating in a research report on Friday, November 15th. Finally, Wells Fargo & Company lowered their price target on bluebird bio from $3.00 to $2.00 and set an "equal weight" rating on the stock in a report on Wednesday, September 25th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, bluebird bio presently has an average rating of "Hold" and an average target price of $3.03.

bluebird bio Stock Performance

Shares of bluebird bio stock traded up $0.38 during trading hours on Wednesday, reaching $0.74. The company had a trading volume of 77,908,594 shares, compared to its average volume of 7,663,903. bluebird bio has a one year low of $0.29 and a one year high of $5.53. The business has a fifty day simple moving average of $0.45 and a 200 day simple moving average of $0.73. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The firm has a market cap of $143.17 million, a PE ratio of -0.39 and a beta of 0.72.

bluebird bio (NASDAQ:BLUE - Get Free Report) last posted its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. The business had revenue of $18.57 million for the quarter. On average, analysts anticipate that bluebird bio will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of bluebird bio

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of bluebird bio by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company's stock valued at $13,438,000 after purchasing an additional 1,723,081 shares in the last quarter. AQR Capital Management LLC grew its position in shares of bluebird bio by 315.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company's stock valued at $1,223,000 after buying an additional 1,013,144 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company's stock valued at $193,000 after buying an additional 355,562 shares during the last quarter. FMR LLC grew its position in shares of bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company's stock valued at $1,289,000 after buying an additional 186,903 shares during the last quarter. Finally, Barclays PLC grew its position in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company's stock valued at $130,000 after buying an additional 184,605 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company's stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.